Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Levonordefrin is a synthetic sympathomimetic amine and the levoisomer of nordefrin. It is primarily used as a vasoconstrictor in local anesthetic solutions for dental procedures and as a topical nasal decongestant. Levonordefrin acts mainly by stimulating adrenergic receptors—specifically as a non-selective agonist at α1-, α2-, and β-adrenergic receptors with preferential activity at the α2-adrenergic receptor. Its pharmacologic effects are similar to those of epinephrine but it is more stable and less potent in raising blood pressure or causing vasoconstriction at equal concentrations. Levonordefrin does not cross the blood-brain barrier and its side effects are peripheral. It is rapidly metabolized by catechol-O-methyltransferase with an elimination half-life of 1–3 minutes[1][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on levonordefrin.